BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
Study on the mechanism of Coptis chinensis Franch. And its main active components in treating Alzheimer's disease based on SCFAs using Orbitrap Fusion Lumos Tribrid MS. ✅
Go to Publication ✅
Journal of ethnopharmacology (J Ethnopharmacol ) Vol: 311 Issue Pages: 116392 Pub: 2023 Jul 15 Epub: 2023 Apr 5 Authors Xie M , Gu S , Hong Y , Liu Y , Rong X , Lu W , Liu H , Algradi AM , Naseem A , Shu Z , Wang Q , |
|
|
Coptidis rhizoma inhibits growth and proteases of oral bacteria. ✅
Oral diseases (Oral Dis ) Vol: 6 Issue 5 Pages: 297-302 Pub: 2000 Sep Epub: Authors Hu JP , Takahashi N , Yamada T , |
|
|
Coptisine alleviates colitis through modulating gut microbiota and inhibiting TXNIP/NLRP3 inflammasome. ✅
Go to Publication ✅
Journal of ethnopharmacology (J Ethnopharmacol ) Vol: 335 Issue Pages: 118680 Pub: 2024 Aug 8 Epub: 2024 Aug 8 Authors Li C , Deng L , Pu M , Ye X , Lu Q , |
|
|
Coptisine alleviates colitis through modulating gut microbiota and inhibiting TXNIP/NLRP3 inflammasome. ✅
Go to Publication ✅
Journal of ethnopharmacology (J Ethnopharmacol ) Vol: 335 Issue Pages: 118680 Pub: 2024 Aug 8 Epub: 2024 Aug 8 Authors Li C , Deng L , Pu M , Ye X , Lu Q , |
|
|
Coptisine alleviates colitis through modulating gut microbiota and inhibiting TXNIP/NLRP3 inflammasome. ✅
Go to Publication ✅
Journal of ethnopharmacology (J Ethnopharmacol ) Vol: 335 Issue Pages: 118680 Pub: 2024 Aug 8 Epub: 2024 Aug 8 Authors Li C , Deng L , Pu M , Ye X , Lu Q , |
|
|
Coptisine alleviates colitis through modulating gut microbiota and inhibiting TXNIP/NLRP3 inflammasome. ✅
Go to Publication ✅
Journal of ethnopharmacology (J Ethnopharmacol ) Vol: 335 Issue Pages: 118680 Pub: 2024 Aug 8 Epub: 2024 Aug 8 Authors Li C , Deng L , Pu M , Ye X , Lu Q , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
